Study on the Immune Mechanism of Lianhua Qingwen Capsule/Granule on Nasal Epithelial Cells of Patients Infected with COVID-19

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200066842

Enrollment

Unknown

Registered

2022-12-19

Start date

2022-12-20

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus

Interventions

symptomatic treatment+Lianhua Qingwen capsule Group:None

symptomatic treatment group:None

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18, = 70. 2. People with positive nucleic acid test result or positive throat swab antigen and slight clinical infection. 3. Subjects understood and accepted the process and restrictions of this study, voluntarily participated in this clinical study, and signed a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Subjects known to be allergic to the ingredients or products of Lianhua Qingwen, or allergic constitution (including allergic reactions to other drugs). 2. There are other factors that the researcher thinks are not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame
Proportion of patients with major symptoms relieved;	—

Countries

China

Contacts

Public ContactZhang Zhanbo

haoqing1992@126.com13068768911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026